Annemarie Shepherd1, Gregory Riely2, Frank Detterbeck3, Charles B Simone4, Usman Ahmad5, James Huang6, Robert Korst7, Arun Rajan8, Andreas Rimner9. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Thoracic Surgery, Yale University, New Haven, Connecticut. 4. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Department Thoracic Surgery, Cleveland Clinic, Cleveland, Ohio. 6. Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Department Thoracic Surgery, Valley Hospital, New Jersey. 8. Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 9. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: rimnera@mskcc.org.
Abstract
INTRODUCTION: Thymic carcinomas are rare epithelial malignancies with limited data to guide management. METHODS: To identify areas of agreement and variability in current clinical practice, a 16-question electronic survey was given to members of the International Thymic Malignancy Interest Group (ITMIG). Areas of controversy were discussed with the Thymic Carcinoma Working Group and consensus was achieved, as described. RESULTS: A total of 100 ITMIG members responded. There was general agreement regarding the role for multimodality therapy with definitive surgical resection in physically fit patients with advanced but resectable disease. Areas of controversy included the need for histologic confirmation before surgery, the role of adjuvant therapy, the optimal first-line chemotherapy regimen, and the recommended treatment course for marginally resectable disease with invasion into the great vessels, pericardium, and lungs. CONCLUSIONS: The results of the questionnaire provide a description of the management of thymic carcinoma by 100 ITMIG members with a specific interest or expertise in thymic malignancies. Although there was agreement in some areas, clinical practice appears to vary significantly. There is a great need for collaborative research to identify optimal evaluation and treatment strategies. Given the need for multimodality therapy in many cases, a multidisciplinary discussion of the management of patients with thymic carcinoma is critical.
INTRODUCTION:Thymic carcinomas are rare epithelial malignancies with limited data to guide management. METHODS: To identify areas of agreement and variability in current clinical practice, a 16-question electronic survey was given to members of the International Thymic Malignancy Interest Group (ITMIG). Areas of controversy were discussed with the Thymic Carcinoma Working Group and consensus was achieved, as described. RESULTS: A total of 100 ITMIG members responded. There was general agreement regarding the role for multimodality therapy with definitive surgical resection in physically fit patients with advanced but resectable disease. Areas of controversy included the need for histologic confirmation before surgery, the role of adjuvant therapy, the optimal first-line chemotherapy regimen, and the recommended treatment course for marginally resectable disease with invasion into the great vessels, pericardium, and lungs. CONCLUSIONS: The results of the questionnaire provide a description of the management of thymic carcinoma by 100 ITMIG members with a specific interest or expertise in thymic malignancies. Although there was agreement in some areas, clinical practice appears to vary significantly. There is a great need for collaborative research to identify optimal evaluation and treatment strategies. Given the need for multimodality therapy in many cases, a multidisciplinary discussion of the management of patients with thymic carcinoma is critical.
Authors: F Hirai; T Yamanaka; K Taguchi; H Daga; A Ono; K Tanaka; Y Kogure; J Shimizu; T Kimura; J Fukuoka; Y Iwamoto; H Sasaki; K Takeda; T Seto; Y Ichinose; K Nakagawa; Y Nakanishi Journal: Ann Oncol Date: 2014-11-17 Impact factor: 32.976
Authors: Sara A Hayes; James Huang; Jennifer Golia Pernicka; Jane Cunningham; Junting Zheng; Chaya S Moskowitz; Michelle S Ginsberg Journal: Ann Thorac Surg Date: 2018-03-11 Impact factor: 4.330
Authors: Luis Cabezón-Gutiérrez; Parham Khosravi-Shahi; Sara Custodio-Cabello; Maria García-Martos; Magda Palka-Kotlowska; Ana Isabel Franco-Moreno Journal: Cureus Date: 2018-07-14
Authors: Imran H Mohiuddin; Muhammad Furqan; Gerald Clamon; John Keech; Carryn Anderson; Mark C Smith; John M Buatti; Bryan G Allen Journal: Ann Radiat Ther Oncol Date: 2017-11-22